Kai Ti Chang

US Patent:

7375183, May 20, 2008

Filed:

Oct 5, 2000

Appl. No.:

09/684599

Inventors:

Ira Pastan - Potomac MD, US
Kai Chang - Rockville MD, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C07K 1/00
C07K 17/02

US Classification:

530350, 530402, 530403

Abstract:

This invention relates to the discovery of a differentiation antigen termed mesothelin which is associated with mesotheliomas and ovarian cancers. Mesothelin is about 69 kD in its full-length form. The invention includes uses for the amino acid and nucleic acid sequences for mesothelin, recombinant cells expressing it, methods for targeting and/or inhibiting the growth of cells bearing mesothelin, methods for detecting the antigen and its expression level as an indication of the presence of tumor cells, and kits for such detection.

US Patent:

20090280556, Nov 12, 2009

Filed:

Jan 28, 2008

Appl. No.:

12/021151

Inventors:

Ira Pastan - Potomac MD, US
Kai Chang - Rockville MD, US

Assignee:

The Govt. of the U.S.A. ad represented by the Secretary of the Dept. of Health & Human services - Rockville MD

International Classification:

C12N 1/21
C07H 21/04

US Classification:

43525233, 536 231

Abstract:

This invention relates to the discovery of a differentiation antigen termed mesothelin which is associated with mesotheliomas and ovarian cancers. Mesothelin is about 69 kD in its full-length form. The invention includes uses for the amino acid and nucleic acid sequences for mesothelin, recombinant cells expressing it, methods for targeting and/or inhibiting the growth of cells bearing mesothelin, methods for detecting the antigen and its expression level as an indication of the presence of tumor cells, and kits for such detection.

US Patent:

55253377, Jun 11, 1996

Filed:

May 6, 1994

Appl. No.:

8/239101

Inventors:

Mark C. Willingham - Bethesda MD
Kai Chang - Silver Spring MD
Ira Pastan - Potomac MD

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

A61K 3516
A61K 3900
A61K 39395

US Classification:

4241561

Abstract:

Monoclonal antibody K1 binds to an epitope on the surface of cells of some human tumors, but not to many important normal tissues. Unlike similar antigenic sites such as CA125, this epitope is not shed into the plasma of patients with mesothelioma, e. g. with ovarian cancer. Since the K1 monoclonal antibody is therefore not neutralized by circulating antigen immediately upon injection into the bloodstream, and since K1 allows efficient entry of coupled toxins into cells, the K1 monoclonal antibody can be used in the diagnosis of mesotheliomas.

US Patent:

53209567, Jun 14, 1994

Filed:

Nov 16, 1992

Appl. No.:

7/977727

Inventors:

Mark C. Willingham - Bethesda MD
Kai Chang - Silver Spring MD
Ira Pastan - Potomac MD

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

A61K 3500
A61K 3516
C07K 1528

US Classification:

4351722

Abstract:

The invention provides novel monoclonal antibodies and the hybridomas that secrete them. The antibodies can be used for the diagnosis of a number of cancers, such as ovarian, esophageal and cervical carcinomas. A preferred antibody is secreted by a hybridoma deposited with the ATCC and has Accession No. HB 10570.

US Patent:

58173137, Oct 6, 1998

Filed:

Apr 8, 1996

Appl. No.:

8/629053

Inventors:

Mark C. Willingham - Bethesda MD
Kai Chang - Silver Spring MD
Ira Pastan - Potomac MD

Assignee:

The United States of America as represented by the Secretary of the
Department of Health and Human Services - Washington DC

International Classification:

A61K 39395
C07K 1630

US Classification:

4241781

Abstract:

The invention provides a novel treatment of cancer using a monoclonal antibody that recognizes cell surface antigens present on a number of tumor cells, including ovarian, esophageal and cervical carcinomas. A preferred monoclonal antibody is secreted by a hybridoma deposited with the ATCC and has Accession NO. HB 10570.

US Patent:

61534307, Nov 28, 2000

Filed:

Dec 17, 1998

Appl. No.:

9/215035

Inventors:

Ira Pastan - Potomac MD
Kai Chang - Silver Spring MD

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

C12N 516
C12N 1579
C12N 1509
C07H 2102
C07H 2104

US Classification:

435325

Abstract:

This invention relates to the discovery of a differentiation antigen termed mesothelin which is associated with mesotheliomas and ovarian cancers. Mesothelin is about 69 kD in its full-length form. The invention includes uses for the amino acid and nucleic acid sequences for mesothelin, recombinant cells expressing it, methods for targeting and/or inhibiting the growth of cells bearing mesothelin, methods for detecting the antigen and its expression level as an indication of the presence of tumor cells, and kits for such detection.

US Patent:

60835028, Jul 4, 2000

Filed:

Jan 12, 1998

Appl. No.:

8/776271

Inventors:

Ira Pastan - Potomac MD
Kai Chang - Silver Spring MD

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

A61K 39395
C12P 2108
C12N 520

US Classification:

4241781

Abstract:

This invention relates to the discovery of a differentiation antigen termed mesothelin which is associated with mesotheliomas and ovarian cancers. Mesothelin is about 69 kD in its full-length form. The invention includes uses for the amino acid and nucleic acid sequences for mesothelin, recombinant cells expressing it, methods for targeting and/or inhibiting the growth of cells bearing mesothelin, methods for detecting the antigen and its expression level as an indication of the presence of tumor cells, and kits for such detection.